Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

Bai, Rilan; Cui, Jiuwei

doi:10.3389/fimmu.2022.890166

Cited by 18 publications

(15 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, metabolic interventions that promote the glycolytic or mitochondrial pathways in TILs can improve their persistence and effector functions in the tumor microenvironment. 100,101 When combining immunometabolism and immunotherapy, it is essential to consider timing, dosage, and administration order.…”

Section: Combination Therapies: Immunometabolism and Immunotherapymentioning

confidence: 99%

Discovering the strength of immunometabolism in cancer therapy: Employing metabolic pathways to enhance immune responses

Huldani,

Malviya,

Rodrigues

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Immunometabolism, which studies cellular metabolism and immune cell function, is a possible cancer treatment. Metabolic pathways regulate immune cell activation, differentiation, and effector functions, crucial to tumor identification and elimination. Immune evasion and tumor growth can result from tumor microenvironment metabolic dysregulation. These metabolic pathways can boost antitumor immunity. This overview discusses immune cell metabolism, including glycolysis, oxidative phosphorylation, amino acid, and lipid metabolism. Amino acid and lipid metabolic manipulations may improve immune cell activity and antitumor immunity. Combination therapy using immunometabolism‐based strategies may enhance therapeutic efficacy. The complexity of the metabolic network, biomarker development, challenges, and future approaches are all covered, along with a summary of case studies demonstrating the effectiveness of immunometabolism‐based therapy. Metabolomics, stable isotope tracing, single‐cell analysis, and computational modeling are also reviewed for immunometabolism research. Personalized and combination treatments are considered. This review adds to immunometabolism expertise and sheds light on metabolic treatments' ability to boost cancer treatment immunological response. Also, in this review, we discussed the immune response in cancer treatment and altering metabolic pathways to increase the immune response against malignancies.

show abstract

Section: Combination Therapies: Immunometabolism and Immunotherapymentioning

confidence: 99%

Discovering the strength of immunometabolism in cancer therapy: Employing metabolic pathways to enhance immune responses

Huldani,

Malviya,

Rodrigues

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…More attention should be focused on seeking combination strategies for modulating TME. 6 There is promising evidence of the effectiveness of bacteria/bacteria-derived membrane particles in the modulation of TME/TAM and the controlled targeted drug delivery to cancer. They can overcome physical barriers, target and accumulate in tumor tissues and initiate antitumor immune responses.…”

Section: Abstract Dmentioning

confidence: 99%

Improvement of Targeted Therapy by E. coli Phage-lysate Vaccination: Tumor Microenvironment Modulation and Magnetic Nanoparticle Delivery Enhancement in Tumor Tissue

Ghambashidze¹,

Chikhladze²,

Saladze³

et al. 2023

Georgian Biomedical News

View full text Add to dashboard Cite

BACKGROUND.The tumor microenvironment (TME) has an essential role in cancer development. TME reduces the drug and nanoparticle delivery in tumor tissue and minimizes the treatment outcomes. The new therapeutic strategies of TME reprogramming have shown great promise. One such strategy is TME modulation by the E. coli phage-lysate (EcPHL) vaccination with TME modification and enhancement of magnetic nanoparticles (mNP) uptake by tumor tissue. OBJECTIVES In the current study, we aimed to evaluate the effects of EcPHL vaccination on TME and mNP distribution in the tumor tissue. METHODS Experiments were carried out on 20-25 g BALB/c male mice. EcPHL intraperitoneal vaccinations (0,25 ml, 3x, with 3-day intervals) were initiated after 6 days of the Ehrlich ascites carcinoma (EAC) cells subcutaneous inoculation and intratumoral administration of mNP (5 mg/cm3) -on the 4 th day after the last administration of EcPHL. Tumor volume was measured using a Vernier caliper. Tumor tissue samples, and the spread of mNPs in tumor tissue were estimated using microscope Leica DM6B, Motic Easy Scan Pro scanner (Ultrahigh NA APO 20X [NA 0,75], resolution 40X:0,25 mm/pixel). RESULTSThe mean tumor volume (MTV) was significantly reduced in EcPHL-vaccinated mice. The morphological investigation has shown an increased number of immunocompetent cells, basically macrophages, around the atypical cells in the tumor stroma, infiltrating the inflammatory regions and necrotic areas in the center of the tumor tissue. The inflammatory infiltrations with macrophages were prevalent in the necrotic areas. After mNP injection, the pigment was spread at a distance from the injection site as concentrated masses in extracellular regions of tumor tissue. Areas of inflammatory infiltration and concentration of iron-containing cells were significantly higher in the EcPHL-vaccinated mice compared to unvaccinated, and iron-containing macrophages were detected at a much greater distance from the injection site. CONCLUSIONS EcPHL stimulates anticancer responses, inhibits tumor growth, and enhance the distribution of mNP in tumor tissue. KEYWORDS Cancer; E. coli phage-lysate (EcPHL); magnetic/iron nanoparticles (mNP); Tumor microenvironment (TME).

show abstract

“…Nevertheless, the effectiveness of immunotherapy varies greatly among different populations, tumors, and individuals, and only a fraction of patients benefit from the treatment (Wang et al, 2021). Studies have demonstrated that tumor immune microenvironment (TIME) plays essential roles in the pathogenesis of cancer, and its heterogeneity determines the immunotherapeutic effect to a certain extent (Bai and Cui, 2022). Therefore, significant efforts have been made to identify reliable predictive biomarkers of response and resistance to immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive pan-cancer analysis of N7-methylguanosine regulators: Expression features and potential implications in prognosis and immunotherapy

et al. 2022

View full text Add to dashboard Cite

Although immunotherapy has made great strides in cancer therapy, its effectiveness varies widely among individual patients as well as tumor types, and there is an urgent need to develop biomarkers for effectively assessing immunotherapy response. In recent years, RNA methylation regulators have demonstrated to be novel potential biomarkers for prognosis as well as immunotherapy of cancers, such as N6-methyladenine (m6A) and 5-methylcytosine (m5C). N7-methylguanosine (m7G) is a prevalent RNA modification in eukaryotes, but the relationship between m7G regulators and prognosis as well as tumor immune microenvironment is still unclear. In this study, a pan-cancer analysis of 26 m7G regulators across 17 cancer types was conducted based on the bioinformatics approach. On the one hand, a comprehensive analysis of expression features, genetic variations and epigenetic regulation of m7G regulators was carried out, and we found that the expression tendency of m7G regulators were different among tumors and their aberrant expression in cancers could be affected by single nucleotide variation (SNV), copy number variation (CNV), DNA methylation and microRNA (miRNA) separately or simultaneously. On the other hand, the m7Gscore was modeled based on single sample gene set enrichment analysis (ssGSEA) for evaluating the relationships between m7G regulators and cancer clinical features, hallmark pathways, tumor immune microenvironment, immunotherapy response as well as pharmacotherapy sensitivity, and we illustrated that the m7Gscore exhibited tight correlations with prognosis, several immune features, immunotherapy response and drug sensitivity in most cancers. In conclusion, our pan-cancer analysis revealed that m7G regulators may exert critical roles in the tumor progression and immune microenvironment, and have the potential as biomarkers for predicting prognosis, immunotherapy response as well as candidate drug compounds for cancer patients.

show abstract

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

Cited by 18 publications

References 110 publications

Discovering the strength of immunometabolism in cancer therapy: Employing metabolic pathways to enhance immune responses

Discovering the strength of immunometabolism in cancer therapy: Employing metabolic pathways to enhance immune responses

Improvement of Targeted Therapy by E. coli Phage-lysate Vaccination: Tumor Microenvironment Modulation and Magnetic Nanoparticle Delivery Enhancement in Tumor Tissue

Comprehensive pan-cancer analysis of N7-methylguanosine regulators: Expression features and potential implications in prognosis and immunotherapy

Contact Info

Product

Resources

About